GRCE — Grace Therapeutics Share News
0.000.00%
Last trade - 00:00Grace Therapeutics Q1 net loss widens on impairment charges
Grace Therapeutics falls after FDA declines to approve stroke drug
NASDAQ RESUMED AT 01:57 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:52 PM
NASDAQ RESUMED AT 01:51 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:46 PM
NASDAQ RESUMED AT 01:45 PM
FDA declines Grace's stroke drug over manufacturing and packaging issues (updated)
Brief: Grace Therapeutics Says FDA Issued Complete Response Letter For GTx-104 NDA
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
NASDAQ TRADE HALT HALT NEWS PENDING AT 12:27 PM
U.S. STOCKS ON THE MOVE-BlackRock, MDA Space, Revolution Medicines
U.S. STOCKS ON THE MOVE-Bloom, J&J, CarMax
U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
Grace Therapeutics rises after late‑stage win for brain bleeding drug
Brief: Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Brief: Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
Grace Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary
Grace Therapeutics, Inc expected to post a loss of 22 cents a share - Earnings Preview